Sample Size Requirements for Multivariate Models to Predict Between-Patient Differences in Best Treatments of Major Depressive Disorder
暂无分享,去创建一个
Ronald C. Kessler | Ekaterina Sadikova | Alex Luedtke | R. Kessler | E. Sadikova | Alexander Luedtke
[1] Maurizio Fava,et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. , 2006, The New England journal of medicine.
[2] R. DeRubeis,et al. Treatment Selection in Depression. , 2018, Annual review of clinical psychology.
[3] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[4] I. Lipkovich,et al. Tutorial in biostatistics: data‐driven subgroup identification and analysis in clinical trials , 2017, Statistics in medicine.
[5] L. Bero,et al. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. , 2014, The Cochrane database of systematic reviews.
[6] M. Trivedi,et al. Evidence-Based Recommendations for the Prescription of Exercise for Major Depressive Disorder , 2013, Journal of psychiatric practice.
[7] M. J. van der Laan,et al. The International Journal of Biostatistics Targeted Maximum Likelihood Learning , 2011 .
[8] P. Muglia,et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. , 2010, The American journal of psychiatry.
[9] Zachary D. Cohen,et al. The Personalized Advantage Index: Translating Research on Prediction into Individualized Treatment Recommendations. A Demonstration , 2014, PloS one.
[10] P. Llorca,et al. Investigational drugs in recent clinical trials for treatment-resistant depression , 2017, Expert review of neurotherapeutics.
[11] Mark J van der Laan,et al. Targeted Learning of the Mean Outcome under an Optimal Dynamic Treatment Rule , 2015, Journal of causal inference.
[12] P. Cuijpers,et al. Effectiveness of a Web-Based Guided Self-help Intervention for Outpatients With a Depressive Disorder: Short-term Results From a Randomized Controlled Trial , 2016, Journal of medical Internet research.
[13] R. Kessler,et al. Undertreatment of people with major depressive disorder in 21 countries , 2017, British Journal of Psychiatry.
[14] C. Nemeroff,et al. Personalized medicine: Prediction of disease vulnerability in mood disorders , 2016, Neuroscience Letters.
[15] Alan Frazer,et al. Vagal Nerve Stimulation for Treatment-Resistant Depression , 2017, Neurotherapeutics.
[16] Ashutosh Kumar Singh,et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.
[17] D. Kupfer,et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. , 2003, The Psychiatric clinics of North America.
[18] Erin LeDell,et al. Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring , 2015, Journal of acquired immune deficiency syndromes.
[19] R. Kessler. The costs of depression. , 2012, The Psychiatric clinics of North America.
[20] J. Lurie,et al. Pros and cons of pragmatic clinical trials. , 2013, Journal of comparative effectiveness research.
[21] Ian Roberts,et al. Systematic review of prognostic models in traumatic brain injury , 2006, BMC Medical Informatics Decis. Mak..
[22] Stuart J Pocock,et al. The science of risk models , 2012, European journal of preventive cardiology.
[23] M. Pencina,et al. Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives , 2014, Biometrical journal. Biometrische Zeitschrift.
[24] Roumen Milev,et al. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. , 2012, Current pharmaceutical design.
[25] P. Saltiel,et al. Major depressive disorder: mechanism-based prescribing for personalized medicine , 2015, Neuropsychiatric disease and treatment.
[26] Arnoud Arntz,et al. Predicting Optimal Outcomes in Cognitive Therapy or Interpersonal Psychotherapy for Depressed Individuals Using the Personalized Advantage Index Approach , 2015, PloS one.
[27] Alan E Hubbard,et al. Simulation methods to estimate design power: an overview for applied research , 2011, BMC medical research methodology.
[28] G. Andersson,et al. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. , 2008, The Journal of clinical psychiatry.
[29] W. Brown,et al. Antidepressants versus placebo in major depression: an overview , 2015, World psychiatry : official journal of the World Psychiatric Association.
[30] D. Kupfer,et al. Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .
[31] L. Erin,et al. AUC-Maximizing Ensembles through Metalearning , 2016 .
[32] R. Kessler. The potential of predictive analytics to provide clinical decision support in depression treatment planning , 2018, Current opinion in psychiatry.
[33] H. Kraemer,et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. , 2016, Journal of psychiatric research.
[34] T. Vos,et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature , 2012, Psychological Medicine.
[35] Ying Lu,et al. Evaluating the improvement in diagnostic utility from adding new predictors , 2010, Biometrical journal. Biometrische Zeitschrift.
[36] Helen S Mayberg,et al. Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial , 2012, Trials.
[37] Eric B. Laber,et al. Inference about the expected performance of a data-driven dynamic treatment regime , 2014, Clinical trials.
[38] J. Hibbard,et al. How well do patient activation scores predict depression outcomes one year later? , 2014, Journal of Affective Disorders.
[39] S Greenland,et al. Tests for interaction in epidemiologic studies: a review and a study of power. , 1983, Statistics in medicine.
[40] S. Wisniewski,et al. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol , 2011, Trials.
[41] R. Kessler,et al. Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder , 2016, Epidemiology and Psychiatric Sciences.
[42] C. Durand. Does Raising Type 1 Error Rate Improve Power to Detect Interactions in Linear Regression Models? A Simulation Study , 2013, PloS one.
[43] M. J. van der Laan,et al. Super-Learning of an Optimal Dynamic Treatment Rule , 2016, The international journal of biostatistics.
[44] Christine Stewart,et al. Health Care Contacts in the Year Before Suicide Death , 2014, Journal of General Internal Medicine.
[45] E. Isometsä,et al. Pharmacological and psychosocial treatment of depression in primary care: Low intensity and poor adherence and continuity. , 2016, Journal of affective disorders.
[46] M. J. van der Laan,et al. STATISTICAL INFERENCE FOR THE MEAN OUTCOME UNDER A POSSIBLY NON-UNIQUE OPTIMAL TREATMENT STRATEGY. , 2016, Annals of statistics.
[47] Ewout W Steyerberg,et al. Estimating treatment effects for individual patients based on the results of randomised clinical trials , 2011, BMJ : British Medical Journal.
[48] G. Andersson,et al. Time to remission from mild to moderate depressive symptoms: One year results from the EVIDENT-study, an RCT of an internet intervention for depression. , 2017, Behaviour research and therapy.
[49] R. Todd Ogden,et al. Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study , 2017, Contemporary clinical trials communications.
[50] Stephanie Kovalchik,et al. Assessing heterogeneity of treatment effect in a clinical trial with the proportional interactions model , 2013, Statistics in medicine.
[51] M. Arns,et al. Personalized Medicine: Review and Perspectives of Promising Baseline EEG Biomarkers in Major Depressive Disorder and Attention Deficit Hyperactivity Disorder , 2016, Neuropsychobiology.
[52] R. DeRubeis,et al. Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study , 2018, Psychological Medicine.
[53] W. E. Craighead,et al. Combination psychotherapy and antidepressant medication treatment for depression: for whom, when, and how. , 2014, Annual review of psychology.
[54] M. J. van der Laan,et al. Statistical Applications in Genetics and Molecular Biology Super Learner , 2010 .
[55] S. Rose. Mortality risk score prediction in an elderly population using machine learning. , 2013, American journal of epidemiology.
[56] P. A. Bradley,et al. Developing a practical suicide risk prediction model for targeting high‐risk patients in the Veterans health Administration , 2017, International journal of methods in psychiatric research.
[57] M. J. van der Laan,et al. Mortality prediction in intensive care units with the Super ICU Learner Algorithm (SICULA): a population-based study. , 2015, The Lancet. Respiratory medicine.
[58] Ellen Frank,et al. A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. , 2013, JAMA psychiatry.
[59] Richard Dobson,et al. A comparison of machine learning methods for classification using simulation with multiple real data examples from mental health studies , 2013, Statistical methods in medical research.
[60] T. Friede,et al. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review , 2016, Journal of biopharmaceutical statistics.
[61] S. Murphy,et al. Optimal dynamic treatment regimes , 2003 .
[62] K. Jolly,et al. A randomised controlled trial of the effectiveness of self-weighing as a weight loss intervention , 2014, International Journal of Behavioral Nutrition and Physical Activity.
[63] D. Wasserman,et al. Psychiatric diagnoses and suicide: revisiting the evidence. , 2004, Crisis.
[64] A. Serretti,et al. Progress and prospects in pharmacogenetics of antidepressant drugs , 2016, Expert opinion on drug metabolism & toxicology.
[65] Gregory M. Garrison,et al. Time to Remission for Depression with Collaborative Care Management (CCM) in Primary Care , 2016, The Journal of the American Board of Family Medicine.
[66] K. Hirano,et al. Impossibility Results for Nondifferentiable Functionals , 2012 .
[67] A. Franco,et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. , 2013, JAMA psychiatry.
[68] James M. Robins,et al. Optimal Structural Nested Models for Optimal Sequential Decisions , 2004 .